Stock Track | PROCEPT BioRobotics Plunges 6.05% After Hours Despite Q3 Beat, 2026 Guidance Disappoints

Stock Track

Nov 05, 2025

Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking guidance appears to have disappointed investors, overshadowing its strong quarterly performance.

PROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million was also better than the expected loss of $10.2 million. However, the focus shifted to the company's outlook for fiscal year 2026.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% growth over the previous year, its 2026 revenue guidance raised concerns. The company projects 2026 revenue to be in the range of $410 to $430 million, indicating a growth of 26% to 32% compared to the 2025 guidance. This growth rate, while still robust, marks a deceleration from the current year's expected growth, potentially explaining the negative after-hours reaction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130342641"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130342641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130342641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 06:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130342641","market":"us","top_or_hot":-1,"title":"Stock Track | PROCEPT BioRobotics Plunges 6.05% After Hours Despite Q3 Beat, 2026 Guidance Disappoints","media":"Stock Track","content":"<p>Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking guidance appears to have disappointed investors, overshadowing its strong quarterly performance.</p>\n\n<p>PROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million was also better than the expected loss of $10.2 million. However, the focus shifted to the company's outlook for fiscal year 2026.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% growth over the previous year, its 2026 revenue guidance raised concerns. The company projects 2026 revenue to be in the range of $410 to $430 million, indicating a growth of 26% to 32% compared to the 2025 guidance. This growth rate, while still robust, marks a deceleration from the current year's expected growth, potentially explaining the negative after-hours reaction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PROCEPT BioRobotics Plunges 6.05% After Hours Despite Q3 Beat, 2026 Guidance Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PROCEPT BioRobotics Plunges 6.05% After Hours Despite Q3 Beat, 2026 Guidance Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 06:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking guidance appears to have disappointed investors, overshadowing its strong quarterly performance.</p>\n\n<p>PROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million was also better than the expected loss of $10.2 million. However, the focus shifted to the company's outlook for fiscal year 2026.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% growth over the previous year, its 2026 revenue guidance raised concerns. The company projects 2026 revenue to be in the range of $410 to $430 million, indicating a growth of 26% to 32% compared to the 2025 guidance. This growth rate, while still robust, marks a deceleration from the current year's expected growth, potentially explaining the negative after-hours reaction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"","article_id":"1130342641","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130342641","pubTimestamp":1762295474,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"个股追踪|PROCEPT BioRobotics盘后暴跌6.05%，尽管第三季度表现出色，2026年指引令人失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1},"content_text":"Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking guidance appears to have disappointed investors, overshadowing its strong quarterly performance.\nPROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million was also better than the expected loss of $10.2 million. However, the focus shifted to the company's outlook for fiscal year 2026.\nWhile PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% growth over the previous year, its 2026 revenue guidance raised concerns. The company projects 2026 revenue to be in the range of $410 to $430 million, indicating a growth of 26% to 32% compared to the 2025 guidance. This growth rate, while still robust, marks a deceleration from the current year's expected growth, potentially explaining the negative after-hours reaction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}